Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 4/20 | 0.64 |
| ▸ | TOP2A | P11388 | 2/20 | 0.57 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.57 |
| ▸ | NISCH | Q9Y2I1 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7764675 | 0.98 | PRMT1 (0.62) | PRMT1TOP2ATOP2BNISCHALDH1A1 | |
| SCHEMBL549207 | 0.86 | TOP2A (0.57) | PRMT1TOP2ATOP2BNISCHALDH1A1 | |
| Hydrochloric Acid SCHEMBL7761917 | 0.85 | TOP2A (0.58) | PRMT1TOP2ATOP2BNISCHALDH1A1 | |
| SCHEMBL8235330 | 0.79 | PRMT1 (1.00) | PRMT1TOP2ATOP2BNISCHALDH1A1 | |
| SCHEMBL6363258 | 0.77 | PRMT1 (0.59) | PRMT1NISCH | |
| SCHEMBL5476725 | 0.77 | NISCH (0.79) | TOP2ATOP2BNISCHALDH1A1CYP1A2 | |
| SCHEMBL5028113 | 0.76 | PRMT1 (0.68) | PRMT1TOP2ATOP2BNISCHALDH1A1 | |
| Hydrochloric Acid SCHEMBL6362869 | 0.76 | PRMT1 (0.57) | PRMT1TOP2ATOP2BNISCH | |
| SCHEMBL13135587 | 0.76 | NISCH (0.86) | PRMT1NISCH | |
| SCHEMBL5032928 | 0.75 | PRMT1 (0.67) | PRMT1TOP2ATOP2BNISCHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| EP-2033959-B1 | Tetrahydropyranoquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-04-27 | — | — | EP | disclosed |
| WO-2005027842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004002430-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | PRMT1 26/4885TOP2A 23/4885TOP2B 27/4885 |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | PRMT1 2728/4885TOP2A 59/4885TOP2B 104/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | PRMT1 2584/4885TOP2A 63/4885TOP2B 43/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | PRMT1 1095/4885TOP2A 156/4885TOP2B 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.